Collegium Pharmaceutical (COLL) Non-Current Debt (2016 - 2026)
Collegium Pharmaceutical has reported Non-Current Debt over the past 11 years, most recently at $542.1 million for Q4 2025.
- For Q4 2025, Non-Current Debt fell 1.57% year-over-year to $542.1 million; the TTM value through Dec 2025 reached $542.1 million, down 1.57%, while the annual FY2025 figure was $542.1 million, 1.57% down from the prior year.
- Non-Current Debt for Q4 2025 was $542.1 million at Collegium Pharmaceutical, up from $505.6 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $565.7 million in Q3 2024 and troughed at $61.7 million in Q4 2021.
- A 5-year average of $342.7 million and a median of $375.7 million in 2022 define the central range for Non-Current Debt.
- Biggest five-year swings in Non-Current Debt: surged 544.73% in 2022 and later crashed 57.13% in 2024.
- Year by year, Non-Current Debt stood at $61.7 million in 2021, then surged by 544.73% to $397.6 million in 2022, then crashed by 44.23% to $221.7 million in 2023, then soared by 148.4% to $550.7 million in 2024, then dropped by 1.57% to $542.1 million in 2025.
- Business Quant data shows Non-Current Debt for COLL at $542.1 million in Q4 2025, $505.6 million in Q3 2025, and $520.6 million in Q2 2025.